Crkl Efficiently Mediates Cell Proliferation, Migration, and Invasion Induced by TGF-β Pathway in Glioblastoma

被引:24
作者
Lv, Shunzeng [1 ]
Qin, Juan [2 ]
Yi, Ruiyang [3 ]
Coreman, Melody [1 ]
Shi, Ranran [1 ]
Kang, Huihui [1 ]
Yao, Chengjun [4 ]
机构
[1] Shandong Univ, Dept Med, Jinan 250100, Shandong, Peoples R China
[2] Dongnan Univ, Dept Diag, Nanjing, Jiangsu, Peoples R China
[3] Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA
[4] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200040, Peoples R China
关键词
CrkL; TGF-beta pathway; Activation; Glioblastoma; GROWTH-FACTOR-BETA; THERAPEUTIC TARGET; ADAPTER PROTEIN; SMAD PROTEINS; EXPRESSION; TGF-BETA-1; RECEPTORS; GLIOMA; GENE; KERATINOCYTES;
D O I
10.1007/s12031-013-0096-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Crk-like (CrkL) is an adapter protein that has crucial roles in cell proliferation, adhesion, and migration. However, the expression pattern and potential mechanism of CrkL protein in glioblastoma multiforme (GBM) have not been fully elucidated. To determine roles of CrkL in cell signaling, proliferation, and migration, small interfering RNAs and plasmids transfection were used to suppress or overexpress CrkL in U87 and U251; soft-agar assay and wound-healing assay were used to observe cell invasiveness, migration, and proliferation. Erk1/2, Smad2, and matrix metalloproteinase 9 (MMP9) were also analyzed by western blot. CrkL was expressed in U87 and U251 cell lines and can be activated by transforming growth factor-beta 1 (TGF-beta 1) in vitro; CrkL knockdown significantly suppressed the expression of phosph-ERK1/2 and MMP9 but enhanced phosph-Smad2 expression compared with control (p < 0.001). Overexpression of CrkL against control upregulated phosph-ERK1/2 and MMP9 and, at the same time, downregulated phosph-Smad2 (p < 0.01). On the other hand, CrkL knockdown could significantly affect U87 and U251 invasiveness (p < 0.01) and wound closure (p < 0.01) using soft-agar assay and wound-healing assay. These studies suggest that CrkL efficiently mediates cell proliferation, migration, and invasion induced by TGF-beta pathway in glioblastoma. Furthermore, CrkL can be used as a potential and efficient therapeutic target of GBM and may also mediate other signaling pathway.
引用
收藏
页码:1046 / 1051
页数:6
相关论文
共 33 条
[1]   Theaflavins retard human breast cancer cell migration by inhibiting NF-κB via p53-ROS cross-talk [J].
Adhikary, Arghya ;
Mohanty, Suchismita ;
Lahiry, Lakshmishri ;
Hossain, Dewan Md Sakib ;
Chakraborty, Samik ;
Das, Tanya .
FEBS LETTERS, 2010, 584 (01) :7-14
[2]   CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells [J].
Arai, Ayako ;
Aoki, Mae ;
Yan Weihua ;
Jin, Aishun ;
Miura, Osamu .
CELLULAR SIGNALLING, 2006, 18 (12) :2162-2171
[3]  
Bell Emily S, 2012, Genes Cancer, V3, P341, DOI 10.1177/1947601912459951
[4]   Crk and CrkL adaptor proteins: networks for physiological and pathological signaling [J].
Birge, Raymond B. ;
Kalodimos, Charalampos ;
Inagaki, Fuyuhiko ;
Tanaka, Shinya .
CELL COMMUNICATION AND SIGNALING, 2009, 7
[5]  
Butowski Nicholas A, 2006, Clin Neurosurg, V53, P106
[6]   Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-β1 involves MAPK, Smad and AP-1 signalling pathways [J].
Davies, M ;
Robinson, M ;
Smith, E ;
Huntley, S ;
Prime, S ;
Paterson, I .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 95 (05) :918-931
[7]   SHP-1 protein tyrosine phosphatase associates with the adaptor protein CrkL [J].
Evren, Sevan ;
Ma, Xue-Zhong ;
Sakac, Darinka ;
Branch, Donald R. .
EXPERIMENTAL HEMATOLOGY, 2012, 40 (12) :1055-1059
[8]   Crk family adaptors - signalling complex formation and biological roles [J].
Feller, SM .
ONCOGENE, 2001, 20 (44) :6348-6371
[9]   Nucleocytoplasmic shuttling of Smad proteins [J].
Hill, Caroline S. .
CELL RESEARCH, 2009, 19 (01) :36-46
[10]   TGF-β as a therapeutic target in high grade gliomas - Promises and challenges [J].
Joseph, Justin V. ;
Balasubramaniyan, Veerakumar ;
Walenkamp, Annemiek ;
Kruyt, Frank A. E. .
BIOCHEMICAL PHARMACOLOGY, 2013, 85 (04) :478-485